secwatch.observer — SEC 8-K summary
======================================

Issuer:     Veradermics, Inc (MANE)
CIK:        0001827635
Form:       8-K
Filed at:   2026-08-11T12:15:58+00:00
Accession:  0001827635-26-000028
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Veradermics Q2 net loss $23.5M; positive Phase 2 female hair-loss data, cash $819.9M
--------------------------------------------------------------------------------

- Q2 2026 net loss $23.5M vs $15.6M YoY; R&D $18.6M (up $4.3M), G&A $10.9M (up $9.2M).
- Phase 2 Study 207: mean TAHC increase 22.7 (QD) and 23.3 (BID) hairs/cm² at Month 6; 88.9%/90.0% improved on AAIRS.
- Completed enrollment of Phase 2/3 Study 306 (556 female PHL patients); topline expected 1H27.
- Phase 3 Study 304 topline and 12-month Study 302 data both anticipated in 2H26.
- Cash $819.9M as of June 30, 2026; $472M raised in May 2026, funding into 2030.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1827635/000182763526000028/0001827635-26-000028-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1827635/000182763526000028/mane-20260811.htm
  HTML page:      https://secwatch.observer/filing/0001827635-26-000028

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer